Research ExplorerPublicationsContinuous high dosing of lenalidomide in relapsed, refracto...

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Standard

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. / Hütter-Krönke, Marie Luise; Fiedler, Walter; Kündgen, Andrea; Krauter, Jürgen; von Lilienfeld-Toal, Marie; Döhner, Hartmut; Schlenk, Richard.

In: HAEMATOLOGICA, Vol. 104, No. 2, 02.2019, p. E63-E64.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Hütter-Krönke, ML, Fiedler, W, Kündgen, A, Krauter, J, von Lilienfeld-Toal, M, Döhner, H & Schlenk, R 2019, 'Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study', HAEMATOLOGICA, vol. 104, no. 2, pp. E63-E64. https://doi.org/10.3324/haematol.2018.199794

APA

Hütter-Krönke, M. L., Fiedler, W., Kündgen, A., Krauter, J., von Lilienfeld-Toal, M., Döhner, H., & Schlenk, R. (2019). Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. HAEMATOLOGICA, 104(2), E63-E64. https://doi.org/10.3324/haematol.2018.199794

Vancouver

Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H et al. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. HAEMATOLOGICA. 2019 Feb;104(2):E63-E64. https://doi.org/10.3324/haematol.2018.199794

Bibtex

@article{f5469a528eb24e9cb6eb480d92e88582,
title = "Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study",
keywords = "Journal Article",
author = "H{\"u}tter-Kr{\"o}nke, {Marie Luise} and Walter Fiedler and Andrea K{\"u}ndgen and J{\"u}rgen Krauter and {von Lilienfeld-Toal}, Marie and Hartmut D{\"o}hner and Richard Schlenk",
note = "Letter to the Editor",
year = "2019",
month = feb,
doi = "10.3324/haematol.2018.199794",
language = "English",
volume = "104",
pages = "E63--E64",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

RIS

TY - JOUR

T1 - Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

AU - Hütter-Krönke, Marie Luise

AU - Fiedler, Walter

AU - Kündgen, Andrea

AU - Krauter, Jürgen

AU - von Lilienfeld-Toal, Marie

AU - Döhner, Hartmut

AU - Schlenk, Richard

N1 - Letter to the Editor

PY - 2019/2

Y1 - 2019/2

KW - Journal Article

U2 - 10.3324/haematol.2018.199794

DO - 10.3324/haematol.2018.199794

M3 - Other (editorial matter etc.)

C2 - 30171028

VL - 104

SP - E63-E64

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 2

ER -